Prostate cancer (PCa) is one of the most commonly diagnosed cancers and the leading cause of cancer-related deaths in men worldwide. Androgen deprivation therapy remains the first-line treatment for patients with locally advanced and metastatic prostate cancer but also increases the incidence of castration-resistant prostate cancer (CRPC). Therefore, more potent androgen receptor pathway inhibitors (i.e ENZ and ABI), have shown substantial improvements in the management of these late diseases. However, therapy resistance will occur inevitably. The progression of PCa is complicated and varied. Understanding the mechanism of therapy resistance development and the biology of clinical stage progression could provide better therapeutic strategies for PCa patients and prolong their life.
The ultimate goal of this Research Topic is to discuss the clinical characteristics of prostate cancer (especially the lethal PCa, such as metastatic CRPC and neuroendocrine prostate cancer), and to uncover novel mechanisms underlying prostate cancer development and progression. Moreover, the valuable experimental models for PCa study are also focused on this topic, which will benefit to translation and precision medicine of PCa. We welcome submissions covering recent conceptual or methodological advances (Review or Mini-review), promising research or treatment trends (perspective or opinion), the innovative clinical technique for treatment or diagnosis, and novel research findings (original research article) in the field of PCa study. These may include but are not limited to the followings:
• Mechanisms of therapeutic resistance development in prostate cancer
• Valuable models that mimic the biological characteristic of PCa
• Clinical features of PCa progression
• Innovative clinical techniques for treatment or diagnosis of PCa
• Studies on prostate cancer metastasis
• Novel drug candidates or therapeutic strategies for PCa patients
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Topic editor Dr. Dong Lin is employed as a Research Scientist by BC Cancer Research Centre and declares no competing interests with regards to the Research Topic Subject. All other Topic Editors declare no competing interests with regards to the Research Topic subject.
Prostate cancer (PCa) is one of the most commonly diagnosed cancers and the leading cause of cancer-related deaths in men worldwide. Androgen deprivation therapy remains the first-line treatment for patients with locally advanced and metastatic prostate cancer but also increases the incidence of castration-resistant prostate cancer (CRPC). Therefore, more potent androgen receptor pathway inhibitors (i.e ENZ and ABI), have shown substantial improvements in the management of these late diseases. However, therapy resistance will occur inevitably. The progression of PCa is complicated and varied. Understanding the mechanism of therapy resistance development and the biology of clinical stage progression could provide better therapeutic strategies for PCa patients and prolong their life.
The ultimate goal of this Research Topic is to discuss the clinical characteristics of prostate cancer (especially the lethal PCa, such as metastatic CRPC and neuroendocrine prostate cancer), and to uncover novel mechanisms underlying prostate cancer development and progression. Moreover, the valuable experimental models for PCa study are also focused on this topic, which will benefit to translation and precision medicine of PCa. We welcome submissions covering recent conceptual or methodological advances (Review or Mini-review), promising research or treatment trends (perspective or opinion), the innovative clinical technique for treatment or diagnosis, and novel research findings (original research article) in the field of PCa study. These may include but are not limited to the followings:
• Mechanisms of therapeutic resistance development in prostate cancer
• Valuable models that mimic the biological characteristic of PCa
• Clinical features of PCa progression
• Innovative clinical techniques for treatment or diagnosis of PCa
• Studies on prostate cancer metastasis
• Novel drug candidates or therapeutic strategies for PCa patients
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Topic editor Dr. Dong Lin is employed as a Research Scientist by BC Cancer Research Centre and declares no competing interests with regards to the Research Topic Subject. All other Topic Editors declare no competing interests with regards to the Research Topic subject.
